Michael T Milano1, Jimm Grimm2, Scott G Soltys3, Ellen Yorke4, Vitali Moiseenko5, Wolfgang A Tomé6, Arjun Sahgal7, Jinyu Xue8, Lijun Ma9, Timothy D Solberg9, John P Kirkpatrick10, Louis S Constine11, John C Flickinger12, Lawrence B Marks13, Issam El Naqa14. 1. Department of Radiation Oncology, University of Rochester, Rochester, New York. Electronic address: michael_milano@urmc.rochester.edu. 2. Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Radiation Oncology, Stanford University Medical Center, Stanford, California. 4. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Radiation Medicine and Applied Sciences, University of California, San Diego, La Jolla, California. 6. Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York. 7. Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. 8. Department of Radiation Oncology, NYU Langone Medical Center, New York, New York. 9. Department of Radiation Oncology, University of California, San Francisco, San Francisco, California. 10. Departments of Radiation Oncology and Surgery, Duke Cancer Institute, Durham, North Carolina. 11. Department of Radiation Oncology, University of Rochester, Rochester, New York. 12. Departments of Radiation Oncology and Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 13. Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina. 14. Department of Radiation Oncology, Lineberger Cancer Center, University of North Carolina, Chapel Hill, North Carolina.
Abstract
PURPOSE: Dosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation. METHODS AND MATERIALS: Eligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION). RESULTS: Thirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in <1% RION risks include 12 Gy in 1 fraction (which is greater than our recommendation of 10 Gy in 1 fraction), 20 Gy in 3 fractions, and 25 Gy in 5 fractions. Omitting multi-fraction data (and thereby eliminating uncertainties associated with dose conversions), a single-fraction dose of 10 Gy was associated with a 1% RION risk. Insufficient details precluded modeling of NTCP risks after prior radiation therapy. CONCLUSIONS: Optic apparatus NTCP and tolerance doses after single- and multi-fraction stereotactic radiosurgery are presented. Additional standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses and better define RION NTCP after SRS/fSRS.
PURPOSE: Dosimetric and clinical predictors of radiation-induced optic nerve/chiasm neuropathy (RION) after single-fraction stereotactic radiosurgery (SRS) or hypofractionated (2-5 fractions) radiosurgery (fSRS) were analyzed from pooled data that were extracted from published reports (PubMed indexed from 1990 to June 2015). This study was undertaken as part of the American Association of Physicists in Medicine Working Group on Stereotactic Body Radiotherapy, investigating normal tissue complication probability (NTCP) after hypofractionated radiation. METHODS AND MATERIALS: Eligible studies described dose delivered to optic nerve/chiasm and provided crude or actuarial toxicity risks, with visual endpoints (ie, loss of visual acuity, alterations in visual fields, and/or blindness/complete vision loss). Studies of patients with optic nerve sheath tumors, optic nerve gliomas, or ocular/uveal melanoma were excluded to obviate direct tumor effects on visual outcomes, as were studies not specifying causes of vision loss (ie, tumor progression vs RION). RESULTS: Thirty-four studies (1578 patients) were analyzed. Histologies included pituitary adenoma, cavernous sinus meningioma, craniopharyngioma, and malignant skull base tumors. Prior resection (76% of patients) did not correlate with RION risk (P = .66). Prior irradiation (6% of patients) was associated with a crude 10-fold increased RION risk versus no prior radiation therapy. In patients with no prior radiation therapy receiving SRS/fSRS in 1-5 fractions, optic apparatus maximum point doses resulting in <1% RION risks include 12 Gy in 1 fraction (which is greater than our recommendation of 10 Gy in 1 fraction), 20 Gy in 3 fractions, and 25 Gy in 5 fractions. Omitting multi-fraction data (and thereby eliminating uncertainties associated with dose conversions), a single-fraction dose of 10 Gy was associated with a 1% RION risk. Insufficient details precluded modeling of NTCP risks after prior radiation therapy. CONCLUSIONS: Optic apparatus NTCP and tolerance doses after single- and multi-fraction stereotactic radiosurgery are presented. Additional standardized dosimetric and toxicity reporting is needed to facilitate future pooled analyses and better define RION NTCP after SRS/fSRS.
Authors: N Menjot de Champfleur; S Menjot de Champfleur; D Galanaud; N Leboucq; A Bonafé Journal: Diagn Interv Imaging Date: 2013-07-23 Impact factor: 4.026
Authors: Michael T Milano; Kenneth Y Usuki; Kevin A Walter; Douglas Clark; Michael C Schell Journal: Cancer Treat Rev Date: 2011-05-14 Impact factor: 12.111
Authors: R C Miller; R L Foote; R J Coffey; D A Gorman; J D Earle; P J Schomberg; R W Kline Journal: Int J Radiat Oncol Biol Phys Date: 1997-12-01 Impact factor: 7.038
Authors: Vitali Moiseenko; Jimm Grimm; Ellen Yorke; Andrew Jackson; Anthony Yip; Minh-Phuong Huynh-Le; Anand Mahadevan; Kenneth Forster; Michael T Milano; Jona A Hattangadi-Gluth Journal: Cureus Date: 2020-10-05
Authors: Michael Xiang; Cynthia Chan; Lei Wang; Khushboo Jani; Samantha J Holdsworth; Michael Iv; Erqi L Pollom; Scott G Soltys Journal: Br J Radiol Date: 2019-05-22 Impact factor: 3.039
Authors: Vitali Moiseenko; Lawrence B Marks; Jimm Grimm; Andrew Jackson; Michael T Milano; Jona A Hattangadi-Gluth; Minh-Phuong Huynh-Le; Niclas Pettersson; Ellen Yorke; Issam El Naqa Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-23 Impact factor: 8.013
Authors: Mohamed H Khattab; Alexander D Sherry; Mark C Xu; Patrick Kelly; Joshua L Anderson; Guozhen Luo; Lola B Chambless; Anthony J Cmelak; Albert Attia Journal: J Neurol Surg B Skull Base Date: 2020-05-05
Authors: Michael T Milano; Jimm Grimm; Andrzej Niemierko; Scott G Soltys; Vitali Moiseenko; Kristin J Redmond; Ellen Yorke; Arjun Sahgal; Jinyu Xue; Anand Mahadevan; Alexander Muacevic; Lawrence B Marks; Lawrence R Kleinberg Journal: Int J Radiat Oncol Biol Phys Date: 2020-09-11 Impact factor: 8.013